Updated treatment of castration-resistant prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 1136-1140, 2014.
Artículo
en Chino
| WPRIM
| ID: wpr-319552
ABSTRACT
Most prostate cancer cases ultimately relapse after a period of initial response to castration therapy and progress to intractable castration-resistant prostate cancer (CRPC). Hardly any therapeutic options currently used can improve the 2- to 3-year survival of the patient. Recently, some new drugs for the treatment of CRPC through various action mechanisms have been approved, and others are in the advanced stage of clinical trial. This review provides an overview of these new therapeutic agents.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias de la Próstata
/
Cirugía General
/
Orquiectomía
/
Mortalidad
/
Usos Terapéuticos
/
Quimioterapia
/
Neoplasias de la Próstata Resistentes a la Castración
/
Recurrencia Local de Neoplasia
/
Antineoplásicos
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
/
Masculino
Idioma:
Chino
Revista:
National Journal of Andrology
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS